These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16157344)

  • 1. Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.
    Takaya T; Kawashima S; Shinohara M; Yamashita T; Toh R; Sasaki N; Inoue N; Hirata K; Yokoyama M
    Atherosclerosis; 2006 Jun; 186(2):402-10. PubMed ID: 16157344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The angiotensin receptor blocker, telmisartan, reduces and stabilizes atherosclerosis in ApoE and AT1aR double deficient mice.
    Fukuda D; Enomoto S; Hirata Y; Nagai R; Sata M
    Biomed Pharmacother; 2010 Dec; 64(10):712-7. PubMed ID: 20970951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attenuation of focal brain ischemia by telmisartan, an angiotensin II type 1 receptor blocker, in atherosclerotic apolipoprotein E-deficient mice.
    Iwai M; Inaba S; Tomono Y; Kanno H; Iwanami J; Mogi M; Horiuchi M
    Hypertens Res; 2008 Jan; 31(1):161-8. PubMed ID: 18360031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice.
    Blessing E; Preusch M; Kranzhöfer R; Kinscherf R; Marx N; Rosenfeld ME; Isermann B; Weber CM; Kreuzer J; Gräfe J; Katus HA; Bea F
    Atherosclerosis; 2008 Aug; 199(2):295-303. PubMed ID: 18093593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment with the AT1-receptor antagonist telmisartan inhibits biglycan accumulation in murine atherosclerosis.
    Nagy N; Melchior-Becker A; Fischer JW
    Basic Res Cardiol; 2010 Jan; 105(1):29-38. PubMed ID: 19701787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of RGS2 deficiency on the therapeutic effect of telmisartan in angiotensin II-induced aortic aneurysm.
    Matsumoto S; Kamide K; Banno F; Inoue N; Mochizuki N; Kawano Y; Miyata T
    Hypertens Res; 2010 Dec; 33(12):1244-9. PubMed ID: 20882024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olmesartan, a novel angiotensin II type 1 receptor antagonist, reduces severity of atherosclerosis in apolipoprotein E deficient mice associated with reducing superoxide production.
    Shimada K; Murayama T; Yokode M; Kita T; Fujita M; Kishimoto C
    Nutr Metab Cardiovasc Dis; 2011 Sep; 21(9):672-8. PubMed ID: 20399087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telmisartan, ramipril and their combination improve endothelial function in different tissues in a murine model of cholesterol-induced atherosclerosis.
    Schlimmer N; Kratz M; Böhm M; Baumhäkel M
    Br J Pharmacol; 2011 Jun; 163(4):804-14. PubMed ID: 21323898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carvedilol reduces the severity of atherosclerosis in apolipoprotein E-deficient mice via reducing superoxide production.
    Shimada K; Hirano E; Kimura T; Fujita M; Kishimoto C
    Exp Biol Med (Maywood); 2012 Sep; 237(9):1039-44. PubMed ID: 22946091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimulation of the AT2 receptor reduced atherogenesis in ApoE(-/-)/AT1A(-/-) double knock out mice.
    Tiyerili V; Mueller CF; Becher UM; Czech T; van Eickels M; Daiber A; Nickenig G; Wassmann S
    J Mol Cell Cardiol; 2012 Mar; 52(3):630-7. PubMed ID: 22230040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice.
    Iwanami J; Mogi M; Tsukuda K; Min LJ; Sakata A; Jing F; Iwai M; Horiuchi M
    J Hypertens; 2010 Aug; 28(8):1730-7. PubMed ID: 20498620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telmisartan exerts antiatherosclerotic effects by activating peroxisome proliferator-activated receptor-γ in macrophages.
    Matsumura T; Kinoshita H; Ishii N; Fukuda K; Motoshima H; Senokuchi T; Taketa K; Kawasaki S; Nishimaki-Mogami T; Kawada T; Nishikawa T; Araki E
    Arterioscler Thromb Vasc Biol; 2011 Jun; 31(6):1268-75. PubMed ID: 21474824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats.
    Kobayashi N; Ohno T; Yoshida K; Fukushima H; Mamada Y; Nomura M; Hirata H; Machida Y; Shinoda M; Suzuki N; Matsuoka H
    Am J Hypertens; 2008 May; 21(5):576-81. PubMed ID: 18437150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of renal superoxide dismutase by telmisartan therapy in C57BL/6-Ins2(Akita) diabetic mice.
    Fujita H; Fujishima H; Morii T; Sakamoto T; Komatsu K; Hosoba M; Narita T; Takahashi K; Takahashi T; Yamada Y
    Hypertens Res; 2012 Feb; 35(2):213-20. PubMed ID: 22072110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice.
    Iwai M; Chen R; Li Z; Shiuchi T; Suzuki J; Ide A; Tsuda M; Okumura M; Min LJ; Mogi M; Horiuchi M
    Circulation; 2005 Sep; 112(11):1636-43. PubMed ID: 16145000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of angiotensin-(1-7), losartan and their combination on atherosclerotic plaque formation in apolipoprotein E knockout mice.
    Yang J; Sun Y; Dong M; Yang X; Meng X; Niu R; Guan J; Zhang Y; Zhang C
    Atherosclerosis; 2015 Jun; 240(2):544-9. PubMed ID: 25957120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice.
    Wassmann S; Czech T; van Eickels M; Fleming I; Böhm M; Nickenig G
    Circulation; 2004 Nov; 110(19):3062-7. PubMed ID: 15277329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions.
    Yoshii T; Iwai M; Li Z; Chen R; Ide A; Fukunaga S; Oshita A; Mogi M; Higaki J; Horiuchi M
    Hypertens Res; 2006 Jun; 29(6):457-66. PubMed ID: 16940709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.
    Alter ML; Ott IM; von Websky K; Tsuprykov O; Sharkovska Y; Krause-Relle K; Raila J; Henze A; Klein T; Hocher B
    Kidney Blood Press Res; 2012; 36(1):119-30. PubMed ID: 23171828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone.
    Keidar S; Kaplan M; Pavlotzky E; Coleman R; Hayek T; Hamoud S; Aviram M
    Circulation; 2004 May; 109(18):2213-20. PubMed ID: 15123520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.